Längere venöse Thromboembolie-Prophylaxe mit Apixaban vs. kürzere mit Enoxaparin bei kritisch Kranken nicht überlegen

Woitzek, Katja
June 2012
Praxis (16618157);6/6/2012, Vol. 101 Issue 11, p745
Academic Journal
No abstract available.


Related Articles

  • Antidote for new anticoagulants studied. Garrett, Anna D. // Drug Topics;Feb2013, Vol. 157 Issue 2, p32 

    The article discusses various issues related to the pharmaceutical industry. PRT4445 is a new antidote developed by Portola Pharmaceuticals Inc. for factor Xa inhibitors. A new research has shown that stopping dabigatran before radiofrequency catheter ablation for atrial fibrillation (AF) is...

  • CME Questions.  // Internal Medicine Alert;5/15/2010, Vol. 32 Issue 9, p70 

    A quiz concerning several medical topics including superficial venous thrombosis, reduction in cancer mortality, atrial fibrillation is presented.

  • Enoxaparin sodium.  // Reactions Weekly;2/8/2014, Issue 1487, p18 

    The article presents a case study of a 72-year-old woman with rectus sheath haematoma which developed while receiving enoxaparin sodium for atrial fibrillation.

  • Percutaneous methods of left atrial appendage exclusion: an alternative to the internist. Duong L. Le; Khodjaev, Soidjon D.; Morelli, Remo L. // Journal of Community Hospital Internal Medicine Perspectives (JC;2014, Vol. 4 Issue 1, p1 

    Thromboembolic stroke from the left atrial appendage (LAA) is the most feared complication in patients with atrial fibrillation (AF). The cornerstone for the management of chronic non-valvular AF is stroke reduction with oral anticoagulation (OAC). However, poor compliance, maintaining a narrow...

  • Estimating Stroke and Bleeding Risk in Atrial Fibrillation. Crawford, Michael H. // Clinical Cardiology Alert;Sep2012, Vol. 31 Issue 9, p67 

    The author discusses a study to evaluate the comparative utility of four schemes that have been validated in atrial fibrillation (AF) cohorts: CHADS2, CHA2DS2-VASc, HASBLED, and HEMORR2HAGES for assessing the risk of stroke and bleeding in patients with AF, which concluded that CHA2DS2-VASc...

  • Warfarin and absolute risk of hemorrhagic stroke.  // CMAJ: Canadian Medical Association Journal;5/14/2013, Vol. 185 Issue 8, p687 

    A letter to the editor is presented in response to the article "Rates of Hemorrhage During Warfarin Therapy for Atrial Fibrillation" by T Gomes and his colleagues in the April 2013 issue.

  • Atrial Fibrillation Associated Costs for Stroke Hospitalizations of Medicare Beneficiaries in the Stroke Belt of the United States. Guijing Wang; Xin Tong; George, Mary G. // JAFIB: Journal of Atrial Fibrillation; 

    Purpose: To estimate atrial fibrillation (AF)-associated costs for stroke hospitalizations among Medicare beneficiaries aged ≥65 years in a 11-state region called stroke belt in the United States. Methods: Using the 2010 Medicare Provider Analysis and Review File database, we analyzed...

  • Evaluation of Trends of Inpatient Hospitalisation for Significant Haemorrhage in Patients Anticoagulated for Atrial Fibrillation before and after the Release of Novel Anticoagulants. Badal, Madan; Aryal, Madan Raj; Mege, Joan; Chaudhary, Ashok; Donato, Anthony A. // Heart, Lung & Circulation;Jan2015, Vol. 24 Issue 1, p94 

    Compared to Vitamin K antagonists (VKA), novel oral anticoagulants (NOACs) appear to be safer in terms of major bleeding risks with added advantage of having fixed dosing schedules when used in patients with non-valvular atrial fibrillation (AF). We sought to study the differences as sources and...

  • AMPLIFY trial results.  // Hospital Medicine Alert;Sep2013 Pharmacology Watch, p2 

    The article discusses research done on the effects of apixaban and anticoagulant therapy in patients with acute venous thromboembolism (VTE) published online in the July 1, 2013 issue of the "New England Journal of Medicine."


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics